Photocure ASA
OSE:PHO

Watchlist Manager
Photocure ASA Logo
Photocure ASA
OSE:PHO
Watchlist
Price: 57.8 NOK 0.17%
Market Cap: 1.6B NOK

EV/EBITDA
Enterprise Value to EBITDA

25.9
Current
18
Median
12.7
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
25.9
=
Enterprise Value
1.3B NOK
/
EBITDA
49.2m NOK
Market Cap EV/EBITDA
NO
Photocure ASA
OSE:PHO
1.6B NOK 25.9
US
Eli Lilly and Co
NYSE:LLY
761.5B USD 41.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
400.1B USD 13.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 13.6
CH
Roche Holding AG
SIX:ROG
231.8B CHF 11.3
UK
AstraZeneca PLC
LSE:AZN
174.2B GBP 126.7
CH
Novartis AG
SIX:NOVN
198.4B CHF 11.4
US
Merck & Co Inc
NYSE:MRK
225.2B USD 8.9
IE
Endo International PLC
LSE:0Y5F
167.6B USD 267.5
US
Pfizer Inc
NYSE:PFE
141.5B USD 8.5
EBITDA Growth EV/EBITDA to Growth
NO
Photocure ASA
OSE:PHO
Average EV/EBITDA: 397.7
25.9
53%
0.5
US
Eli Lilly and Co
NYSE:LLY
41.8
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.3
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.3
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
126.7
9%
14.1
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
US
Merck & Co Inc
NYSE:MRK
8.9
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
15.6
2-Years Forward
EV/EBITDA
11.5
3-Years Forward
EV/EBITDA
7.3